Pharmaceutical combination preparation and application thereof in preparation of medicine for treating aplastic anemia

An aplastic and pharmaceutical technology, applied in the application of pharmaceuticals, in the field of pharmaceutical combination preparations, can solve only 30-40% of the problems

Pending Publication Date: 2019-10-01
杨婷
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although recent guidelines recommend immunosuppressive therapy (IST) for the treatment of AA, the disease-free survival (EFS) rate of IST is only 30-40% because of late complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical combination preparation and application thereof in preparation of medicine for treating aplastic anemia
  • Pharmaceutical combination preparation and application thereof in preparation of medicine for treating aplastic anemia
  • Pharmaceutical combination preparation and application thereof in preparation of medicine for treating aplastic anemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] During 2013-2017, when 29 patients with aplastic anemia were treated with allogeneic hematopoietic stem cell transplantation, fludarabine 30mg / m was used 3 days before stem cell reinfusion treatment 2 / day fludarabine intravenous infusion for 4 days, at the same time 30mg / kg / day cyclophosphamide intravenous infusion for 4 days, and 10mg / kg / day anti-human T lymphocyte rabbit immune globulin intravenous infusion for 3 days at the same time, finally received Allogeneic hematopoietic stem cell transplantation. The 29 treated patients were followed up until October 2018, and the statistics of the follow-up results are as follows: Table 1:

[0018]

[0019]

[0020]

[0021] Table 1

[0022] VSAA in Table 1 is very severe aplastic anemia. SAA is severe aplastic anemia. NSAA is non-severe aplastic anemia. GVHD is Graft Versus Host Disease. aGVHD is acute graft-versus-host disease. cGVHD is chronic graft versus host disease.

[0023] According to the statistical...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of drug development, in particular to a pharmaceutical combination preparation and application thereof in preparation of medicine for treating aplastic anemia. The pharmaceutical combination preparation consists of fludarabine, cyclophosphamide and anti-human T lymphocyte rabbit immunoglobulin with or without a small dose of busulfan. The pharmaceuticalcombination preparation can achieve a good effect on application of allogeneic hematopoietic stem cell transplantation in treatment of aplastic anemia. The combination preparation can both treat haploid bonding and fully compatible hematopoietic stem cell transplantation. The provided pharmaceutical combination preparation is used for pretreatment, so that stem cell implantation is effectively promoted, the incidence rate of graft versus host diseases, namely GVHD and severe GVHD, is significantly reduced, and the mortality associated with GVHD is reduced.

Description

technical field [0001] The invention relates to the technical field of drug research and development, in particular to a drug combination preparation and its application in the preparation of drugs for treating aplastic anemia. Background technique [0002] Aplastic anemia (AA) is a disease characterized by peripheral blood cell reduction caused by bone marrow failure, among which severe aplastic anemia (SAA) and very severe aplastic anemia (vSAA) have high mortality, threatening patient's life. Although recent guidelines recommend immunosuppressive therapy (IST) for the treatment of AA, the disease-free survival (EFS) rate of IST is only 30-40% because of late complications. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative method for AA. According to the donor source, allogeneic hematopoietic stem cell transplantation can be divided into fully matched and haploid transplantation. Patients need to be pre-treated before transplantation. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K31/675A61K31/52A61P7/06
CPCA61K39/39541A61P7/06A61K31/52A61K31/675A61K2300/00
Inventor 杨婷骆晓峰任金华吴雪琼张钰鑫朱浩杰肖敏陈少桢陈永铨林康昵陈敏敏李芊庄悠然
Owner 杨婷
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap